SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Voltaire — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientVoltaire
Date of birth1694-11-21
IdentifiersMRN HR-EN002-SYN-TD; SSN (made up) 000-02-5174
Document date1778-04-22
AuthorHonorine Delacroix-Mensah, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review of the resection pathology and a trial without catheter; decision on treatment. [S]

History of Present Illness

Voltaire returns a week after the transurethral resection and two days after the sick visit for a catheter-associated infection. He has been afebrile since yesterday morning on cefpodoxime, and the culture grew Escherichia coli sensitive to it. The urine is pale pink without clots. Since the resection he has had a burning ache above the pubic bone and bladder spasms, worst in the evening, rated 5 of 10; acetaminophen when he remembers takes the edge off. He asked for something strong, saying that a friend has offered him drops made with opium. He has had no constipation on polyethylene glycol. The trial without catheter began this morning: the catheter was removed at 8 am and he voided 260 mL before this visit. He came with his assistant and wants to hear the results plainly and to decide today. [S]

ElementDetail
PathologyKeratinizing squamous cell carcinoma invading the muscularis propria, with lymphovascular invasion; no urothelial component or carcinoma in situ
InfectionAfebrile on day 3 of cefpodoxime; Escherichia coli sensitive
PainSuprapubic burning and evening spasm, 5 of 10
Voiding trialCatheter out this morning; voided 260 mL; residual 140 mL
IPSS14 (moderate), from 22 before the catheter

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired after the infection; no fever since yesterday morning; appetite small
GenitourinaryPositivePale pink urine, frequency, burning, and evening spasm after resection; no clots
GastrointestinalNegativeBowels open daily
MusculoskeletalNegativeNo bone pain
PsychiatricPositiveShaken by the diagnosis but composed; wants to keep working

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Diphenhydramine 25 mg oral capsule, one capsule at night for sleep (over the counter)One capsule at bedtimeOral route1777-09-01 to 1778-04-06stoppedS
Tamsulosin 0.4 mg oral capsule, one capsule at bedtimeOne capsule 30 minutes after the evening mealOral route1778-04-06activeS
Polyethylene glycol 3350, 17 g in a glass of water once daily17 g dissolved in water once dailyOral route1776-01-15activeS
Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 7 daysOne tablet twice daily with food for 7 daysOral route1778-04-20 to 1778-04-26completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth three times daily (3 g a day)Two tablets three times daily; no more than 3 g a dayOral route1778-04-22activeS
Oxycodone 5 mg oral tablet, one half tablet (2.5 mg) by mouth every 6 hours if needed for bladder pain not relieved by acetaminophen, no more than three doses a day; 15 tablets dispensedHalf a tablet every 6 hours as needed; no more than three half tablets a dayOral route1778-04-22activeS
Sennosides 8.6 mg oral tablet, two tablets at bedtime while taking oxycodoneTwo tablets at bedtimeOral route1778-04-22activeS
Naloxone 4 mg nasal spray, one spray in one nostril for suspected opioid overdose; call 911; may repeat in 2 to 3 minutes in the other nostrilOne spray for suspected overdose; repeat after 2 to 3 minutes if no responseNasal route1778-04-22activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1778-04-22Body height170cmS
1778-04-22Body weight53.4kgS
1778-04-22Body mass index (BMI) [Ratio]18.5kg/m2S
1778-04-22Systolic blood pressure124mm[Hg]S
1778-04-22Diastolic blood pressure68mm[Hg]S
1778-04-22Heart rate82/minS
1778-04-22Respiratory rate16/minS
1778-04-22Body temperature36.9CelS
1778-04-22Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1778-04-22Hemoglobin [Mass/volume] in Blood10.9g/dL13.2-16.6 g/dLLowS
1778-04-22Leukocytes [#/volume] in Blood by Automated count8.210*3/uL3.4-9.6 10*3/uLNormalS
1778-04-22Platelets [#/volume] in Blood by Automated count25410*3/uL150-400 10*3/uLNormalS
1778-04-22Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
1778-04-22Creatinine [Mass/volume] in Serum or Plasma1.22mg/dL0.74-1.35 mg/dLNormalS
1778-04-22Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1773)/1.73 sq M59mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
1778-04-22US Urinary bladder Volume post void140mLBelow 100 mL; 300 mL or more suggests chronic retentionHighS
1778-04-22International Prostate Symptom Score [IPSS]14{score}S
1778-04-22Pain severity - 0-10 verbal numeric rating [Score] - Reported5{score}S

Physical Exam

Vital signs recorded on 1778-04-22; see the Vital Signs section. [S]

SystemFinding
GeneralThin, alert, and engaged; temperature 36.9 C
CardiovascularBlood pressure 124/68 mmHg; heart rate 82, regular
AbdomenMild suprapubic tenderness; bladder not palpable after voiding; no masses
Lymph nodesNo inguinal or supraclavicular nodes

Problems

ProblemClinical statusVerificationCodeProvenance
Visible blood in the urine for three weeks with clots, and a weak stream, straining, and frequent small voids, in a man of 83; under evaluationresolvedconfirmed R31.0S — Synthetic presenting problem echoing his documented urinary complaints and last illness; superseded by the diagnosis at the third chronic-care visit.
Chronic urinary retention with overflow (post-void residual 460 mL at intake), worsened by a nightly anticholinergic sleep aid; drained by an indwelling catheteractiveconfirmed R33.8S — Synthetic finding echoing the strangury and catheterization documented in his last weeks.
Acute kidney injury from bladder outlet obstruction (creatinine 1.68 mg/dL, from 1.1 mg/dL a year earlier)resolvedconfirmed N17.9S — Synthetic finding; it echoes, without asserting, the later encyclopedia term uremia.
Benign prostatic hyperplasia with lower urinary tract symptoms: prostate about 78 mL on CT, enlarged, firm, and smooth on examination, PSA 6.4 ng/mL with a PSA density of 0.08; no prostate biopsy, by shared decisionactiveconfirmed N40.1S — Synthetic diagnosis echoing the very large prostate described at the 1778 autopsy; whether that prostate was malignant is unknown (CLM-0012).
Squamous cell carcinoma of the bladder, keratinizing, posterior wall extending to the dome, muscle-invasive with extravesical extension (clinical stage cT3b N0 M0, stage IIIA), pure squamous histology without a urothelial component; treated with palliative-intent hypofractionated radiotherapy by shared decisionactiveconfirmed C67.4S — Synthetic modern diagnosis confirmed by resection pathology. His bladder disease at autopsy is documented (D); calling it squamous cell carcinoma is a 2025 retrospective interpretation (R, disputed).
Chronic constipation, lifelong by his account, with long use of laxatives and self-given enemasactiveconfirmed K59.09S — Synthetic modern problem echoing his documented colic, purges, and enemas; no diagnosis of inflammatory bowel disease is made.
Febrile catheter-associated urinary tract infection with Escherichia coli, five days after bladder tumor resection; treated with cefpodoxime and a catheter change; resolvedactiveconfirmed T83.511AS — Synthetic intercurrent infection; it echoes, without asserting, the infected urine described in his last weeks (CLM-0009).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count and kidney function before radiotherapy and before an opioidBefore treatment, then at each visit during treatmentCompleted todayHemoglobin 10.9 g/dL, white count 8.2, platelets 254; creatinine 1.22 mg/dL (eGFR 59), potassium 4.5 mmol/L
LaboratoryUrine culture from the sick visitWith symptoms of catheter-associated infectionCompleted todayEscherichia coli sensitive to cefpodoxime; no change of antibiotic
ImagingStaging: chest imaging and CT or MRI of the abdomen and pelvisBefore treatment of muscle-invasive bladder cancerCompleted todayCT urography and chest CT reviewed with the pathology: cT3b N0 M0; bone scan not needed without bone pain
ExaminationPost-void residual after the trial without catheterAt baseline when retention is suspected, after a trial without catheter, and when symptoms changeCompleted today140 mL after voiding 260 mL
SurveyIPSSBaseline and at every follow-up visit (CMID BPH)Completed today14, moderate, from 22 before the catheter
SurveyPain intensity (0 to 10)At every visit with cancer pain, and before and after any opioidCompleted today5 of 10, suprapubic
ExaminationGeriatric assessment before cancer treatment (G8 screen, function, nutrition, comorbidity, social support)Before choosing cancer treatment in adults 65 and olderCompleted todayG8 11 of 17; independent in self-care, needs help with shopping and travel; BMI 18.5; lives with an assistant. Cognitive screen and Timed Up and Go are booked for the wellness visit next week
Medication safetyOpioid start: risk review, prescription monitoring program, naloxone, bowel regimen, lowest dose of an immediate-release opioid, and a follow-up dateAt the start, then within 1 to 4 weeksCompleted todayPrescription monitoring program clear; no benzodiazepine or other sedative; naloxone and senna prescribed; oxycodone 2.5 mg as needed, 15 tablets; review in two weeks
Medication safetyAlpha-blocker tolerabilityAt each visit in a frail older adultCompleted todayNo dizziness; blood pressure 124/68 mmHg
ReferralRadiation oncology and palliative careWhen treatment is chosenReferredPlanning scan and the first fraction next week; palliative care home visit within two weeks
ImagingBladder cancer surveillance schedule (cystoscopy and cytology for NMIBC; CT every 6 to 12 months after cystectomy)Applies after NMIBC treatment or cystectomyNot indicatedNeither applies: he has muscle-invasive disease treated with palliative-intent radiotherapy, so response is judged by symptoms, with cystoscopy or CT only if they would change care

Goal progress:

Guideline basis: Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026); Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment (Hafeez S, et al.) (2017); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America (2009); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026)

Follow-up: Wellness visit next week; chronic-care review in two weeks, on the day of the second radiotherapy fraction; call for a falling stream, clots, fever, or pain not controlled. Next scheduled visit 1778-04-28: subsequent annual wellness visit at 83. [S]